about
Prognostic value of proliferation in invasive breast cancer: a reviewIntegrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they controlVinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trialTOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinomaIncreased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based studyAssessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.Expert opinion: Reporting needle core biopsies of breast carcinomas.Best Practice No 176: Updated recommendations for HER2 testing in the UKUse of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testingIHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.Serum HER-2 concentration in patients with primary breast cancer.HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.Chromosome instability and benefit from adjuvant anthracyclines in breast cancer.CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation.HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladderEvaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.Trastuzumab in the management of early and advanced stage breast cancer.Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma.Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.Standardized on-slide control for quality assurance in the immunohistochemical assessment of therapeutic target molecules in breast cancer.Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.HER-2/neu expression in germ cell tumours.Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.HER2 gene copy number and breast cancer-specific survival.Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer.Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains.Evaluating HER2 amplification and overexpression in breast cancer.Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations.Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients.
P2860
Q24672660-EF47D59A-D25B-42B9-BCAA-039E2645657DQ30577477-DDF68C95-0A18-49BE-93F1-376BDB28BF25Q33279460-E7B653F1-B546-4771-99E0-B5190142BC87Q34044864-2D0936F9-6208-438F-8B4E-B20E719BB1B1Q34129444-562EDC81-ABC8-490F-A002-2C71E151B388Q35078787-FE12E2D2-3A9F-4B4E-AC4F-3CB44764A994Q35161416-2EE57478-3E5D-4BE5-B0F8-4F84E0EC0354Q35587451-8BE4CE8C-2D79-4A9F-A835-09CC5EBDE6F7Q35588100-3AA96B15-291F-40E9-B077-F045EDC1EEF0Q35588768-98B917C1-969E-41C0-BF18-272B3D45C049Q35769870-B25CBE0D-CFA7-471D-A7E8-F58D5E4EAFBEQ35893399-6902C697-45E7-4BA7-96EC-8FDBEEB9A460Q35984457-F0D5DD1C-5380-4704-B6CC-F48D3E448CEDQ36075278-D02E98BB-61C1-4CEB-9B68-92C171EDEA92Q36623521-BB2DC9CC-522E-457D-84BA-F43143B25EA2Q36671182-278D2F41-BABC-4EF5-A881-E5F3808E2CC3Q37010568-DBBD40FE-4F2F-45B5-AC14-05C5F66FACA2Q37290613-F94C1CAC-187C-4055-8CF7-6D59A191FE89Q37559006-BD729253-46ED-4A8F-B2E7-AB67D10D8AD9Q38089259-530F7865-0A16-402E-8314-F008A709505DQ38440214-43553BF9-3D81-4519-916B-624CAD16FA47Q38444404-FC58F81A-70F0-4C82-9F40-9A93F4D312BDQ38454847-1435BE3D-0258-4903-A41F-5C1191F90F1CQ38455404-F55A57AC-0841-49F5-858F-381712DB3B2EQ40089438-CE29563B-0869-4CE1-BE64-4C6DAF994FE1Q40714642-E54F78DE-205D-41D4-B850-5934EF5F4879Q46841926-442FFD95-5CB2-4796-9661-2CCDCFFB5314Q47915365-C3EDE7F6-680E-410B-AB80-C77E1941FD67Q50767143-16002DF8-A3FF-451B-8FBE-EA9218C34BE2Q52936177-A578E416-E2DF-49AC-9FF0-69CD5E573703Q53227861-B3A6B373-BBB8-4793-9810-EC3631BF07B1Q54197932-E6528AC3-8803-4589-B0F5-2F9EBD2E06BEQ54311896-9B6438AE-EBF7-4D61-AEB2-E9B7AD2172A1Q54696645-2D5B4104-FF84-4ED3-953D-519721B11314
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Recommendations for HER2 testing in the UK.
@ast
Recommendations for HER2 testing in the UK.
@en
type
label
Recommendations for HER2 testing in the UK.
@ast
Recommendations for HER2 testing in the UK.
@en
prefLabel
Recommendations for HER2 testing in the UK.
@ast
Recommendations for HER2 testing in the UK.
@en
P2093
P356
P1476
Recommendations for HER2 testing in the UK.
@en
P2093
Bartlett J
Gusterson B
P2860
P304
P356
10.1136/JCP.53.12.890
P407
P50
P577
2000-12-01T00:00:00Z